Navigation Links
Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/17/2009

ROCKVILLE, Md., March 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2008 fourth quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on March 30, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on March 30, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is USA and Canada (866) 206-6509 International: (703) 639-1108.

A live audio webcast of the conference call will be available at www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EDT. March 30, 2009 through midnight April 1, 2009. To access the replay, dial (888) 266-2081 and enter pass code 1334845.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
2. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
3. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
4. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
5. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
6. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
7. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
8. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
9. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... Do More with OHAUS , With the launch of the new laboratory ... industry, to extending its expertise across the entire laboratory to a range of life ... allowing for its customers to 'Do More' in the lab. , Efficiency and ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy ... cells and tissues by delivering pollen and nectar containing nutrients necessary for growth and ... stay healthy. , Many recent indicators point to a decline in honey bee health. ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... a Series B round of financing in the amount of $6 million. An ... investors participated in the round. , The Series B funding will enable Cybrexa ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):